Abstract
Thromboembolic risk increases with age, but it also increases the risk of bleeding. For security reasons, anticoagulation therapy in older patients have to take into account the different pharmacokinetics of medicines, frequent presence of renal failure, presence of associated diseases and concomitant medications.
Warfarin is the most prescribed drug for thromboembolic disease, but its use is limited by the necessity of dose titration and narrow therapeutic window. New anticoagulants are very promising group of drugs, which gradually replace warfarin.
So far, this treatment is limited to certain groups of specialists. Currently, dabigatran, rivaroxaban and apixaban indicated in patients with atrial fibrillation, pulmonary embolism or thrombosis limb.